Research programme: solute carrier transporters inhibitors - Nirogy Therapeutics
Alternative Names: Monocarboxylate transporters inhibitors - Nirogy Therapeutics; SLCT inhibitors - Nirogy TherapeuticsLatest Information Update: 28 Feb 2025
At a glance
- Originator Nirogy Therapeutics
- Class Anti-inflammatories; Antineoplastics; Small molecules
- Mechanism of Action Monocarboxylic acid transporter inhibitors; Solute carrier protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation; Malignant melanoma; Triple negative breast cancer
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Malignant-melanoma in USA
- 28 Feb 2025 No recent reports of development identified for preclinical development in Triple-negative-breast-cancer in USA
- 28 Feb 2025 No recent reports of development identified for research development in Autoimmune-disorders in USA